Calcium channel blockade and preservation of renal graft function in cyclosporine-treated recipients: A prospective randomized placebo-controlled 2-year study

被引:65
作者
Kuypers, DRJ
Neumayer, HH
Fritsche, L
Budde, K
Rodicio, JL
Vanrenterghem, Y
机构
[1] Univ Hosp Leuven, Dept Nephrol & Renal Transplantat, B-3000 Louvain, Belgium
[2] Univ Berlin, Dept Nephrol & Renal Transplantat, Charite, Berlin, Germany
[3] Hosp 12 Octubre, Dept Nephrol, Madrid, Spain
关键词
lacidipine; calcium channel blocker; renal transplantation; cyclosporine; renal graft function; nephrotoxicity;
D O I
10.1097/01.TP.0000137793.23371.42
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Studies have provided conflicting results as to the protective role of calcium channel blockers (CCB) in cyclosporine-treated patients with regard to blood pressure control and preservation of renal graft function. Lacidipine is a dihydropyridine CCB that possesses antioxidative, anti-atherosclerotic, and anti-adhesion properties and was shown to prevent cyclosporine-induced nephrotoxicity in a rat model. Methods. We conducted a multicenter prospective, randomized, placebo- controlled study in 131 de novo recipients of a cadaveric renal allograft on cyclosporine therapy. The aim of this 2-year study was to assess the effects of lacidipine on graft function (plasma iohexol clearance), renal plasma flow, anastomotic arterial blood flow, deterioration of renal function, blood pressure, acute rejection, and hospitalization rate. Results. A total of 118 recipients were available for intention-to-treat analysis on efficacy (lacidipine:n=59; placebo: n=59). Graft function assessed by serum creatinine concentration and glomerular filtration rate measured as plasma iohexol clearance, was persistently better in lacidipine-treated patients from 1 year onwards (respectively, P<0.01 and P<0.05). Renal plasma flow and anastomotic blood flow were not significantly higher in lacidipine-treated patients. Three patients on lacidipine therapy and four on placebo experienced treatment failure defined as an increase in serum creatinine from baseline of more than 60% (log-rank test: P=0.57). Study groups did not differ in acute rejection rate, trough blood cyclosporine concentrations, blood pressure, number of antihypertensive drugs, hospitalization rate, and adverse event rate. Conclusions. The use of calcium channel blockers in cyclosporine-treated renal recipients results in a significantly better allograft function at 2 years and this effect is independent of blood pressure lowering.
引用
收藏
页码:1204 / 1211
页数:8
相关论文
共 42 条
[11]   ALTERED VASCULAR-RESPONSES IN CYCLOSPORINE-TREATED RATS [J].
GOLUB, MS ;
LUSTIG, S ;
BERGER, ME ;
LEE, DBN .
TRANSPLANTATION, 1989, 48 (01) :116-118
[12]   DELETERIOUS EFFECTS OF CALCIUM-CHANNEL BLOCKADE ON PRESSURE TRANSMISSION AND GLOMERULAR INJURY IN RAT REMNANT KIDNEYS [J].
GRIFFIN, KA ;
PICKEN, MM ;
BIDANI, AK .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (02) :793-800
[13]  
Koomans HA, 2001, TRANSPLANTATION, V72, pS9
[14]   Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives [J].
Leonetti, G ;
Magnani, B ;
Pessina, AC ;
Rappelli, A ;
Trimarco, B ;
Zanchetti, A .
AMERICAN JOURNAL OF HYPERTENSION, 2002, 15 (11) :932-940
[15]   INHIBITION BY DILTIAZEM OF PRESSURE-INDUCED AFFERENT VASOCONSTRICTION IN THE ISOLATED PERFUSED RAT-KIDNEY [J].
LOUTZENHISER, R ;
EPSTEIN, M ;
HORTON, C .
AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (02) :A72-A75
[16]   Effects of the calcium antagonist felodipine on renal haemodynamics, tubular sodium handling, and blood pressure in cyclosporin-treated dermatological patients [J].
Madsen, JK ;
Zachariae, H ;
Pedersen, EB .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (03) :480-484
[17]   Cyclosporin A induces prepro endothelin-1 gene transcription in human endothelial cells [J].
Marsen, TA ;
Weber, F ;
Egink, G ;
Suckau, G ;
Baldamus, CA .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 379 (01) :97-106
[18]   Effects of ACE inhibition on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats on a high-sodium diet [J].
Mervaala, E ;
Lassila, M ;
Vaskonen, T ;
Krogerus, L ;
Lähteenmäki, T ;
Vapaatalo, H ;
Karppanen, H .
BLOOD PRESSURE, 1999, 8 (01) :49-56
[19]   Vasodilatory edema: A common side effect of antihypertensive therapy [J].
Messerli F.H. .
Current Cardiology Reports, 2002, 4 (6) :479-482
[20]   CONVERTING-ENZYME-INHIBITOR VERSUS CALCIUM-ANTAGONIST IN CYCLOSPORINE-TREATED RENAL-TRANSPLANTS [J].
MOURAD, G ;
RIBSTEIN, J ;
MIMRAN, A .
KIDNEY INTERNATIONAL, 1993, 43 (02) :419-425